BofA raised the firm’s price target on UnitedHealth (UNH) to $675 from $660 and keeps a Buy rating on the shares. MCOs were pressured in 2023 from sector rotation, heightened regulatory scrutiny, trend concerns, and deal uncertainty, but broadly the firm remains bullish on managed care and sees 2024 being about the group resetting expectations, getting back to consistent beats and raises and working through overhangs. The firm notes it views Humana (HUM), on which it maintains a Buy rating and $640 price target, as “the most dislocated name in our coverage, with asymmetric upside potential.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on UNH:
- Wex appoints Aimee Cardwell to board of directors
- UNH, HUM, BIIB: 3 Healthcare Stocks to Buy, Say Analysts
- UnitedHealth backs FY23 adjusted EPS view $24.85-$25, consensus $24.95
- UnitedHealth sees FY24 adjusted EPS $27.50-$28, consensus $27.90
- Foot Locker, Teamsters drop drug-benefit managers over costs, WSJ says